SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Butt Z, Rosenbloom SK, Abernethy AP, et al. Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Canc Netw. 2008;6:448-455.
  • 2
    Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13:1084-1096.
  • 3
    Larkin JM, Pyle LM, Gore ME. Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies. Oncologist. 2010;15:1135-1146.
  • 4
    Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer. 2001;92:1664-1668.
  • 5
    Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10:757-763.
  • 6
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
  • 7
    Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-3590.
  • 8
    Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012;30:1371-1377.
  • 9
    Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25:5121-5127.
  • 10
    Brundage MD, Pater JL, Zee B. Assessing the reliability of 2 toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst. 1993;85:1138-1148.
  • 11
    Jensen MP. The validity and reliability of pain measures in adults with cancer. J Pain. 2003;4:2-21.
  • 12
    Kaba H, Fukuda H, Yamamoto S, Ohashi Y. Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0 [in Japanese]. Gan To Kagaku Ryoho. 2004;31:1187-1192.
  • 13
    Bruner DW. Should patient-reported outcomes be mandatory for toxicity reporting in cancer clinical trials? J Clin Oncol. 2007;25:5345-5347.
  • 14
    Cella D, Li JZ, Cappelleri JC, et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol. 2008;26:3763-3769.
  • 15
    Cella D, Yount S, Du H, et al. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol. 2006;4:191-199.
  • 16
    Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
  • 17
    Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-343.
  • 18
    Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. Version 3.0. Bethesda, MD: Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services; 2006. ctep.cancer.gov. Accessed May 29, 2013.
  • 19
    Fairclough D. Design and Analysis of Quality of Life Studies in Clinical Trials. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC; 2010.
  • 20
    Fitzmaurice G, Laird N, Ware J. Applied Longitudinal Analysis. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2011.
  • 21
    Cella D, Michaelson MD, Bushmakin AG, et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer. 2010;102:658-664.
  • 22
    Cappelleri JC, Bushmakin AG. Interpretation of patient-reported outcomes [published online ahead of print February 19, 2013]. Stat Methods Med Res.
  • 23
    Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
  • 24
    Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7:903-909.
  • 25
    Brown DJ, McMillan DC, Milroy R. The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer. 2005;103:377-382.
  • 26
    Mallinson T, Cella D, Cashy J, Holzner B. Giving meaning to measure: linking self-reported fatigue and function to performance of everyday activities. J Pain Symptom Manage. 2006;31:229-241.
  • 27
    Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12:4-10.
  • 28
    Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186-1196.
  • 29
    Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63-74.
  • 30
    Hamidou Z, Dabakuyo TS, Bonnetain F. Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials. Expert Rev Pharmacoecon Outcomes Res. 2011;11:549-559.
  • 31
    Bender R, Lange S. Adjusting for multiple testing–when and how? J Clin Epidemiol. 2001;54:343-349.
  • 32
    Schmidinger M, Arnold D, Szczylik C, Wagstaff J, Ravaud A. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Invest. 2010;28:856-864.
  • 33
    Molina AM, Lin X, Korytowsky B, et al. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1,059 patients treated on clinical trials [abstract]. J Clin Oncol. 2012;30(suppl):Page. Abstract 4542.
  • 34
    Davis MP, Figlin RA, Hutson TE, et al. Asthenia and fatigue as potential biomarkers of sunitinib efficacy in metastatic renal cell carcinoma [abstract]. Eur J Cancer. 2011;47:S135. Abstract 1139.
  • 35
    Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012;104:93-113.
  • 36
    Cancer Therapy Evaluation Program. National Cancer Institute Common Terminology Criteria for Adverse Events. Version 4.0. NIH Pub. No. 09-7473. Bethesda, MD: National Cancer Institute, National Institutes of Health, Department of Health and Human Services; 2009. ctep.cancer.gov. Accessed August 26, 2013.